Wyoming is currently home to 61 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Sheridan, Cody, Cheyenne and Casper. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Mobile Health for Adherence in Breast Cancer Patients
NCT06112613
Recruiting
This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to enhanced usual care (EUC), where patients only use the WiseBag, to monitor medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor. To ensure CDK4/6 inhibitors achieve their full clinical benefit, patients need to take th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Cheyenne Regional Medical Center-West, Cheyenne, Wyoming
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Breast Carcinoma, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Register for Updates
To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring
NCT04597359
Recruiting
This phase II trial studies how well green tea catechins work in preventing progression of prostate cancer from a low risk stage to higher risk stages in men who are on active surveillance. Green tea catechins may stabilize prostate cancer and lower the chance of prostate growing.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
08/08/2024
Locations: Cheyenne Regional Medical Center-West, Cheyenne, Wyoming
Conditions: Prostate Carcinoma
Register for Updates
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
NCT04566328
Recruiting
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spread... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Billings Clinic-Cody, Cody, Wyoming
Conditions: Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
Register for Updates
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
NCT04462406
Recruiting
This phase II trial investigates how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be removed by surgery (unresectable). Anti-PD-1 therapy has become a standard therapy option for patients with unresectable melanoma. This trial is being done to determine if doctors can safely shorten the use of standard of care anti-PD1 therapy for melanoma by using biomarkers seen on PET/CT imaging and tumor biopsy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Cheyenne Regional Medical Center-West, Cheyenne, Wyoming
Conditions: Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Melanoma of Unknown Primary, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Acral Lentiginous Melanoma, Unresectable Melanoma, Unresectable Mucosal Melanoma
Register for Updates
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
NCT03937635
Recruiting
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Cheyenne Regional Medical Center-West, Cheyenne, Wyoming
Conditions: Smoldering Plasma Cell Myeloma
Register for Updates
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
NCT02734537
Recruiting
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet kno... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Big Horn Basin Cancer Center, Cody, Wyoming
Conditions: Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant, Lip and Oral Cavity Squamous Cell Carcinoma, p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oral Cavity Verrucous Carcinoma, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Register for Updates
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
NCT05806515
Recruiting
This phase II trial tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping, or slowing the growth of tumor cells. Giving carboplatin before surgery may shrink tumors in patients with h... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/05/2024
Locations: Billings Clinic-Cody, Cody, Wyoming
Conditions: Prostate Adenocarcinoma, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Register for Updates
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
NCT02201992
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Cheyenne Regional Medical Center-West, Cheyenne, Wyoming
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Register for Updates
Acute Effects of Stimulant Medication in College Students With ADHD
NCT03935646
Recruiting
The investigators will examine the acute effects of stimulant medication on executive functioning. The rationale for the proposed study is to examine the efficacy of stimulants for college students with ADHD and help prevent stimulant misuse among college students without ADHD. The working hypothesis is that stimulants, compared to baseline and placebo conditions, will improve executive functioning for college students with ADHD but not for college students without ADHD. Improvements on executiv... Read More
Gender:
ALL
Ages:
Between 18 years and 29 years
Trial Updated:
06/07/2024
Locations: University of Wyoming, Laramie, Wyoming
Conditions: Attention Deficit Hyperactivity Disorder, Stimulant Use, Working Memory, Change in Sustained Attention, Mood
Register for Updates
Acute Effects of Exercise in College Students With ADHD
NCT03666416
Recruiting
The overall objective of this study is to examine physical exercise as an intervention for ADHD. The rationale for the proposed study is that physical exercise could serve as an effective treatment for college students with ADHD that has low costs, low risks, and ancillary health benefits and may address the limitations of existing treatments. The central hypothesis is that college students with ADHD will exhibit greater degrees of improvement in executive functioning (i.e., sustained attention,... Read More
Gender:
ALL
Ages:
Between 18 years and 29 years
Trial Updated:
06/07/2024
Locations: University of Wyoming, Laramie, Wyoming
Conditions: Attention Deficit Hyperactivity Disorder, Effects of; Exertion, Working Memory, Change in Sustained Attention
Register for Updates
Connect® Myeloid Disease Registry
NCT01688011
Recruiting
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical practice. This disease registry will also evaluate molecular and cellular markers that may provide further prognostic classification which may or may not be predictive of therapy and clinical outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2024
Locations: Memorial Hospital of Laramie County dba Cheyenne Regional Medical Center, Cheyenne, Wyoming
Conditions: Myelodysplastic Syndromes, Primary Myelofibrosis, Leukemia, Myeloid, Acute
Register for Updates
Sustaining Physical Activity After Cancer Exercise Sessions
NCT06359210
Recruiting
The goal of this clinical trial is to develop and test an adaptive physical activity (PA) maintenance intervention for cancer survivors, after participating in a community-based exercise oncology program. The main questions it aims to answer are: * Aim 1: Examine the feasibility and acceptability of the intervention among cancer survivors and community partners. The researchers will utilize quantitative surveys, focus groups, and semi-structured interviews to collect information about feasibili... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/05/2024
Locations: University of Wyoming, Laramie, Wyoming
Conditions: Exercise Oncology, Physical Activity Behavior, Behavior Change Interventions
Register for Updates